In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
LiveHelp online chat

Clinical Trials (PDQ®)

Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Basic Trial Information
Trial Description
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentClosed18 and overNCI, OtherCDR0000353209
CALGB-90202, ECOG-CALGB-90202, SWOG-CALGB-90202, CAN-NCIC-PRC2, NCT00079001

Trial Description


RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy. It is not yet known whether treatment with zoledronate is effective in preventing bone-related events in patients who have prostate cancer and bone metastases.

PURPOSE: This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases.

Further Study Information



  • Compare the time to first skeletal-related events in patients with prostate cancer and bone metastases undergoing androgen deprivation therapy when treated with zoledronate vs placebo.


  • Compare the overall and progression-free survival of patients treated with these regimens.
  • Compare the toxic effects in patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study followed by an open-label study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior skeletal-related event (no vs yes), and serum alkaline phosphatase (< upper limit of normal [ULN] vs ≥ ULN). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive zoledronate IV over 15 minutes on day 1.
  • Arm II: Patients receive placebo IV over 15 minutes on day 1. In both arms, courses repeat every 4 weeks in the absence of disease progression or a skeletal-related event. All patients receive concurrent androgen deprivation therapy. Patients also receive oral calcium and cholecalciferol (vitamin D) supplements daily.

Patients progressing to androgen-independent prostate cancer proceed to open-label therapy comprising zoledronate IV over 15 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or a skeletal-related event.

Patients are followed periodically for approximately 10 years after randomization.

PROJECTED ACCRUAL: A total of 680 patients (340 per treatment arm) will be accrued for this study within 4 years.

Eligibility Criteria


  • Histologically confirmed adenocarcinoma of the prostate
  • No small cell, neuroendocrine, or transitional cell carcinomas
  • At least 1 bone metastasis by bone scan, MRI, CT scan, or plain radiographs
  • Indeterminate lesions should be confirmed by a second imaging method
  • At least 1 bone metastasis with no prior irradiation
  • Concurrent androgen deprivation therapy required, defined as any of the following:
  • Bilateral orchiectomy
  • Gonadotropin-releasing hormone (GnRH) agonist with or without an antiandrogen



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Creatinine clearance ≥ 30 mL/min
  • Corrected calcium ≥ 8.0 mg/dL and < 11.6 mg/dL


  • Fertile patients must use effective contraception


Biologic therapy

  • Concurrent standard biologic response modifiers allowed during open-label therapy only


  • Concurrent standard cytotoxic chemotherapy allowed during open-label therapy only

Endocrine therapy

  • See Disease Characteristics
  • Prior neoadjuvant and/or adjuvant hormonal therapy allowed provided duration of therapy was no more than 6 months AND therapy was discontinued more than 6 months before study entry
  • No more than 6 months since initiation of any of the following hormonal therapies:
  • Orchiectomy
  • GnRH agonist (e.g., leuprolide, goserelin, or triptorelin)
  • Estrogen therapy
  • Antiandrogens (e.g., bicalutamide, flutamide, or nilutamide)
  • Any other therapy known to lower testosterone levels or inhibit testosterone effect
  • No intermittent androgen deprivation therapy except for patients concurrently enrolled on SWOG-9346
  • Concurrent palliative corticosteroids allowed during open-label therapy only
  • Concurrent standard hormonal agents allowed during open-label therapy only


  • See Disease Characteristics
  • No prior radiopharmaceuticals
  • At least 4 weeks since prior radiotherapy
  • Concurrent standard radiotherapy to extraskeletal tumor sites allowed during open-label therapy only


  • See Disease Characteristics


  • No prior bisphosphonates
  • No prior denosumab
  • No other concurrent agents expected to alter osteoclast activity (e.g., denosumab, calcitonin, mithramycin, gallium nitrate, or any other bisphosphonate)
  • Concurrent daily supplemental elemental calcium (500 mg) and a multivitamin containing cholecalciferol (Vitamin D) (400 IU) OR a combination tablet containing both recommended
  • Concurrent standard marketed antineoplastic therapies allowed during open-label therapy only

Trial Contact Information

Trial Lead Organizations/Sponsors

Cancer and Leukemia Group B

National Cancer Institute

Southwest Oncology Group

Eastern Cooperative Oncology Group

NCIC-Clinical Trials Group

Matthew R. SmithStudy Chair

Nirmala BhoopalamStudy Chair

Christopher SweeneyStudy Chair

Fred SaadStudy Chair

Trial Sites

 Indiana University Melvin and Bren Simon Cancer Center
 Noah M Hahn Ph: 317-274-2552
 William N. Wishard Memorial Hospital
 Noah M Hahn Ph: 317-274-2552

Link to the current record.
NLM Identifer NCT00079001 processed this data on October 17, 2013

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top